ObjectiveHealth has announced the launch of ObjectiveScreen, an AI feasibility and recruitment platform that seeks to provide patient identification, prequalification, and retention.
Powered by ObjectiveHealth’s cloud-based, AI and ML algorithms, ObjectiveScreen allows clinical trial sites to connect directly with patient electronic health records (EHRs). Patient health risks are stratified against evidence-based physiologic and molecular biomarkers so users can identify in the most qualified candidates for specific clinical trials.
Each time an EHR is linked, ObjectiveScreen’s algorithms analyze the health data, updating its clinical knowledge base while qualifying patients for the specific trials.
In addition to EHR analysis, ObjectiveScreen can review other patient data, including risk factors and demographic data such as age, gender, ethnicity and socioeconomic status, which can help identify candidates who may not have a diagnosis.
By linking with a healthcare provider’s scheduling application, users of ObjectiveScreen can arrange prescreen visits. ObjectiveScreen’s texting and calling capabilities allow clinical trial site users to communicate directly with patients about appointment reminders and rescheduling options. Users can also monitor patients over multiple visits and recommend new studies if patients did not qualify for a previous trial.
ObjectiveHealth Launches ObjectiveScreen, an Artificial Intelligence-Powered Feasibility and Recruitment Platform to Optimize Clinical Trial Performance. (2023, June 8). Business Wire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.